@article{00e59db2b38642efb142cd0f5878f509,
title = "Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.",
keywords = "Postmenopausal: drug therapy, Postmenopausal: economics, Osteoporosis, Time Factors, Sweden, Postmenopausal: mortality, Quality of Life, Quality-Adjusted Life Years, Support, Non-U.S. Gov't, Age Factors, Aged, Alendronate: economics, Alendronate: therapeutic use, Cohort Studies, Cost-Benefit Analysis, Female, Fractures: economics, Fractures: prevention \& control, Human, Markov Chains",
author = "Olof Johnell and Bengt J{\"o}nsson and Linus J{\"o}nsson and Dennis Black",
year = "2003",
language = "English",
volume = "21",
pages = "305--314",
journal = "PharmacoEconomics",
issn = "1179-2027",
publisher = "Adis International",
number = "5",
}
